Search

The effects of PM 10 on human health were investigated using samples collected in São Carlos city (São Paulo state), by the determination of the concentrations of PAHs and derivatives, together with evaluations of cytotoxicity and the formation of ROS in in vitro tests. In 2016, the mean concentrations of PM 10 , ΣPAHs, Σoxy-PAHs, Σnitro-PAHs, Σsaccharides, and Σions were 21.12 ± 9.90 μg m -3 , 1.47 ± 1.70 ng m -3 , 0.37 ± 0.31 ng m -3 , 0.84 ng m -3 , 119.91 ± 62.14 ng m -3 , and 5.66 ± 4.52 μg m -3 , respectively. The PM 10 concentrations did not exceed the limit thresholds set by national legislation, however, the annual lung cancer risk calculated was 2.59 ± 1.22 cases per 100,000 people, in the dry season, which accounts for the annual risk (April to September). Moreover, the carcinogenic activities of the PAHs mixture were more than 1000-fold higher in the dry season (dry season: BaP eq  = 0.30 ng m -3 ; wet season BaP eq  = 0.02 ng m -3 ). The concentrations of most analytes were also higher during the dry season, as had already been demonstrated in the same city. This was due to reductions in precipitation, relative humidity and air temperature, and increased biomass burning, which was the main source of PM 10 in the city in 2016 (contribution rate of more than 50%). Toxicological results also showed the negative impacts of PM 10 , exposure to PM 10 extracts for 72 h reduced the viability of A549 and MRC5 cells, and the formation of ROS was observed. The cellular responses obtained using combined and individual extracts of PM 10 differed and were sometimes associated with specific compounds. These demonstrate the importance of monitoring PM toxicity using different approaches and the main anthropogenic sources' contribution. Therefore, to improve air quality and human health, existing legislation needs to be modified to incorporate these tests., Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2023 Elsevier Ltd. All rights reserved.)

A class of rotaxane is created, not by encapsulating a conventional linear thread, but rather by wrapping a large cucurbit[10]uril macrocycle about a three-dimensional, cylindrical, nanosized, self-assembled supramolecular helicate as the axle. The resulting pseudo-rotaxane is readily converted into a proper interlocked rotaxane by adding branch points to the helicate strands that form the surface of the cylinder (like branches and roots on a tree trunk). The supramolecular cylinder that forms the axle is itself a member of a unique and remarkable class of helicate metallo-drugs that bind Y-shaped DNA junction structures and induce cell death. While pseudo-rotaxanation does not modify the DNA-binding properties, proper, mechanically-interlocked rotaxanation transforms the DNA-binding and biological activity of the cylinder. The ability of the cylinder to de-thread from the rotaxane (and thus to bind DNA junction structures) is controlled by the extent of branching: fully-branched cylinders are locked inside the cucurbit[10]uril macrocycle, while cylinders with incomplete branch points can de-thread from the rotaxane in response to competitor guests. The number of branch points can thus afford kinetic control over the drug de-threading and release.

In this paper, a series of new ruthenium complexes of the general formula [Ru(NS)(dpphpy)(dppb)]PF 6 ( Ru1 - Ru3 ), where dpphpy = diphenyl-2-pyridylphosphine, NS ligands = 2-thiazoline-2-thiol (tzdt, Ru1 ), 2-mercaptopyrimidine (pySm, Ru2 ), and 4,6-diamino-2-mercaptopyrimidine (damp, Ru3 ), and dppb = 1,4-bis(diphenylphosphino)butane, were synthesized and characterized by elemental analysis, spectroscopic techniques (IR, UV/visible, and 1D and 2D NMR), and X-ray diffraction. In the characterization, the correlation between the phosphorus atoms and their respective aromatic hydrogen atoms of the compounds in the assignment stands outs, by 1 H- 31 P HMBC experiments. The compounds show anticancer activities against A549 (lung) and MDA-MB-231 (breast) cancer cell lines, higher than the clinical drug cisplatin. All of the complexes are more cytotoxic against the cancer cell lines than against the MRC-5 (lung) and MCF-10A (breast) nontumorigenic human cell lines. For A549 tumor cells, cell cycle analysis upon treatment with Ru2 showed that it inhibits the mitotic phase because arrest was observed in the Sub-G1 phase. Additionally, the compound induces cell death by an apoptotic pathway in a dose-dependent manner, according to annexin V-PE assay. The multitargeted character of the compounds was investigated, and the biomolecules were DNA, topoisomerase IB, and proteasome, as well as the fundamental biomolecule in the pharmacokinetics of drugs, human serum albumin. The experimental results indicate that the complexes do not target DNA in the cells. At low concentrations, the compounds showed the ability to partially inhibit the catalytic activity of topoisomerase IB in the process of relaxation of the DNA plasmid. Among the complexes assayed in cultured cells, complex Ru3 was able to diminish the proteasomal chymotrypsin-like activity to a greater extent.

Herein, a robust docking protocol was developed by using a low-cost workflow to highlight the modulation at ATPase domain from Human Topoisomerase-IIα (TOP2A) towards four novel Pd(II)-complexes bearing N,S-donor ligands. In vitro TOP2A inhibition assay confirmed the ability of them to prevent the enzyme functions into concentration ranging at 6.25-25μM. These results exhibited more effectivity than anticancer agent etoposide (35μM) and merbarone (40-50μM). The compounds were screened via Resazurin assay against MCF-7, MDA-MB-231 (Human breast), DU-145 (Human prostate), A549 (Human lung) and Cal27 (Human tongue) tumor cell lines revealing great cytotoxic effects, primarily to MCF-7 (IC 50 =1.81-4.46μM). As well, 1-4 exhibited their selectivity index (SI) higher than cisplatin against HEK-293 (human kidney) normal cells, at least 11.6-fold (SI 1-4 =1.4-5.0; SI cis =0.12). Further, Red Blood Cell hemolytic test suggested in vitro non-toxic character for compound 4, previously evaluated as the most effective TOP2A inhibitor., (Copyright © 2019 Elsevier Inc. All rights reserved.)